BioSpace

Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners

China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run; and the ESMO conference gets underway in Madrid this week, with much-anticipated data from Merck, and Summit Therapeutics.

By BioSpace

1 min read
Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights